Cite
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4)*
MLA
Bieber, Thomas, et al. “Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate‐to‐severe Atopic Dermatitis with Inadequate Response, Intolerance or Contraindication to Ciclosporin: Results from a Randomized, Placebo‐controlled, Phase III Clinical Trial (BREEZE‐AD4)*.” British Journal of Dermatology, vol. 187, no. 3, Sept. 2022, pp. 338–52. EBSCOhost, https://doi.org/10.1111/bjd.21630.
APA
Bieber, T., Reich, K., Paul, C., Tsunemi, Y., Augustin, M., Lacour, J., Ghislain, P., Dutronc, Y., Liao, R., Yang, F. E., Brinker, D., DeLozier, A. M., Meskimen, E., Janes, J. M., & Eyerich, K. (2022). Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4)*. British Journal of Dermatology, 187(3), 338–352. https://doi.org/10.1111/bjd.21630
Chicago
Bieber, Thomas, Kristian Reich, Carle Paul, Yuichiro Tsunemi, Matthias Augustin, Jean‐Philippe Lacour, Pierre‐Dominique Ghislain, et al. 2022. “Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate‐to‐severe Atopic Dermatitis with Inadequate Response, Intolerance or Contraindication to Ciclosporin: Results from a Randomized, Placebo‐controlled, Phase III Clinical Trial (BREEZE‐AD4)*.” British Journal of Dermatology 187 (3): 338–52. doi:10.1111/bjd.21630.